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The treatment of infections caused by resistant microorganisms is limited, and vancomycin (VAN) 
treatment failures for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia are not uncommon, 
even when MRSA clinical isolates are susceptible to VAN. Thus, this study proposed the association 
of VAN with usnic acid and β-lapachone encapsulated into liposomes as a novel therapeutic option for 
infections caused by MRSA. Liposomes containing β-lap (β-lap-lipo) or usnic acid (UA-lipo) were 
prepared by the thin lipid film hydration method followed by sonication. Antimicrobial activity against 
MRSA clinical isolates was investigated by the microdilution method according to the Clinical and 
Laboratory Standards Institute (CLSI). The interaction studies were carried out using the checkerboard 
method and epsilometer test (Etest). The interaction between VAN and β-lap or β-lap-lipo was 
synergistic (FICI = 0.453 and FICI = 0.358, respectively). An additive interaction between VAN and UA 
(FICI = 0.515) was found. UA-lipo resulted in synergism with VAN (FICI = 0.276). The Etest reproduced 
the results obtained by the checkerboard method for approximately 82% of the analysis. Thus, the present 
study demonstrated that VAN in combination with UA-lipo, β-lap or β-lap-lipo synergistically enhanced 
antibacterial activity against MRSA. 
Keywords: β-lapachone. Usnic acid. Liposomes. Methicillin-resistant Staphylococcus aureus (MRSA). 
Synergism.
INTRODUCTION
The emergence worldwide of multiresistant bacteria 
has limited conventional antimicrobial therapy and raises 
serious concerns for public health care systems. From 
this perspective, methicillin-resistant Staphylococcus 
aureus (MRSA) is highly virulent and infections caused 
by MRSA may lead to morbidity and mortality (Zecconi, 
Scali, 2013). Consequently, the scientific community 
is engaged in the development of novel antimicrobial 
agents, including combination therapy of antimicrobials 
and/or encapsulated molecules in drug delivery systems 
(Pinto-Alphandary, Andremont, Couvreur, 2000; Segatore 
et al., 2012). 
In this scenario, the association of antimicrobial agents 
for the treatment of infections caused by multiresistant 
bacteria seems to be significant, since combined therapy 
may prevent the emergence of resistant isolates and also 
increase the spectrum of action of antimicrobials due to 
a synergic effect (Jackson, Agboke, Nwoke, 2009; Silva, 
Mesquita, Ximenes, 2009; Worthington, Melander, 2013). 
Vancomycin (VAN) is the reference drug for the treatment 
of MRSA; however, MRSA strains have presented 
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vancomycin resistance in vivo even when the in vitro profile 
was intermediate or susceptible for this drug (Moise et al., 
2007; Casapao et al., 2015).
Furthermore, new compounds of natural origin 
that exhibit antimicrobial activity have been discovered. 
Therefore, usnic acid (UA), a secondary lichen metabolite, 
and β-lapachone (β-lap), a naphthoquinone derived from 
lapachol extracted from Tabebuia avellanedae bark have 
been studied to establish their antimicrobial activity 
(Lauterwein et al., 1995; Lira et al., 2009; Macedo et 
al., 2013). Although these molecules exhibit proven 
antimicrobial activity, they have limitations, such as low 
water solubility and toxicity, which need to be overcome 
(Kristmundsdoóttir et al., 2002; Nasongkla et al., 2003; 
Han et al., 2004).
Nanostructured systems, such as liposomes, have 
great appeal as a means of delivery of antibiotics to treat 
infections. The encapsulation of antibiotics into liposomes 
offers several advantages, including improvement in their 
therapeutic efficacy and reduction in toxicity (Drulis-
Kawa, Dorotkiewicz-Jach, 2010; Huh, Kwon, 2011). 
Moreover, nanocarriers containing antibiotics can deliver 
drugs to pathogenic bacteria, while avoiding killing 
commensal bacteria of the body, regulating the therapy 
of infections (Abed, Couvreur, 2014). 
Taking into account all  these findings, the 
combination of vancomycin with potential compounds 
of natural origin alone or encapsulated into nanosystems 
represents an option to improve the therapeutic index of 
vancomycin and overcome resistance to this antimicrobial 
agent. Thus, the aim of this study was to evaluate the in 
vitro interactions between vancomycin and usnic acid 
or β-lapachone encapsulated into liposomes against 
methicillin-resistant Staphylococcus aureus (MRSA) 
clinical isolates.
MATERIAL AND METHODS
Material
Vancomycin hydrochloride (VAN) was furnished 
by ABL – Antibióticos do Brasil (Cosmópolis, São 
Paulo, Brazil). Usnic acid (UA), cholesterol (Chol) and 
stearylamine (SA) were purchased from Sigma-Aldrich 
(St. Louis, USA). Soybean phosphatidylcholine (PC) 
(98% Epikuron 200®) was obtained from Lipoid GMBH 
(Ludwigshafen, Germany). Solvents and other chemicals 
were supplied by Merck (Darmstadt, Germany). Etest 
strips with vancomycin were purchased from Oxoid 
(Hampshire, United Kingdom). β-lapachone (β-lap), 
obtained from lapachol by a semi-synthetic route, was 
supplied by Dr. Góes (Department of Antibiotics, UFPE, 
Brazil). Bacterial culture media were purchased from 
HiMedia (Mumbai, India).
Methods
Preparation of liposomes
Liposomes containing β-lapachone (β-lap-lipo) 
or usnic acid (UA-lipo) were prepared according to 
Cavalcanti et al. (2011) and Lira et al. (2009), respectively, 
for comparative purposes in the antimicrobial activity 
evaluation and for the interaction assays with VAN. The 
liposomal formulations were prepared using the thin lipid 
film method followed by sonication. Briefly, lipids (PC, 
Chol and SA) and drugs (β-lap or UA) were dissolved in 
a mixture of CHCl3:CH3OH (3:1, v/v) under magnetic 
stirring. The solvents were then removed under pressure 
for 60 min (37±1°C, 80 rpm), resulting in a thin lipid film. 
This film was then hydrated with phosphate buffer solution 
(pH 7.4). Multilamellar liposomes were then sonicated 
(Vibra Cell; Branson Ultrasonic, Danbury, CT) at 200 W 
and 40 Hz for 300 s to form small unilamellar vesicles. The 
liposomes were characterized by measuring pH, particle 
size, polydispersion index (PDI), zeta potential and 
encapsulation efficiency (%EE), as previously described 
by Cavalcanti et al. (2011) and Lira et al. (2009).
In vitro antimicrobial activity
Bacterial strains
Staphylococcus aureus clinical isolates (10 strains) 
were furnished by the hospital of the Federal University 
of Pernambuco (UFPE, Recife, Brazil) and preserved in 
the Microbiology and Immunology Laboratory (CAV-
UFPE, Brazil). These strains were previously identified 
as MRSA using the disk diffusion method with cefoxitin 
and oxacillin as reference drugs, as well as by screening 
using Müeller-Hinton agar supplemented with 4% NaCl 
and 6 µg/mL of oxacillin according to the Clinical and 
Laboratory Standards Institute (CLSI, 2014) (LMB 01, 
LMB 02, LMB 03, LMB 04, LMB 06, LMB 07, LMB 08, 
LMB 11, LMB 12 and LMB 13). MRSA ATCC 33591 was 
used as the control.
Determination of Minimum Inhibitory 
Concentration (MIC) and Minimum Bactericidal 
Concentration (MBC)
The in vitro antimicrobial activity of VAN, UA 
and UA-lipo was evaluated by the microdilution method 
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according to CLSI (2014). The antimicrobial activity of 
β-lap and β-lap-lipo against these MRSA clinical isolates 
has been previously reported by our research group 
(Cavalcanti et al., 2015). However their interactions with 
vancomycin have not yet been investigated.
Interaction assays
Checkerboard method
The in vitro interactions between VAN and UA, 
UA-lipo, β-lap or β-lap-lipo were evaluated using 
the checkerboard method (An et al., 2011). After 
the determination of MIC, the five MRSA clinical 
isolates most resistant to VAN were selected for this 
analysis. Initially, the 96-well microplates were seeded 
by dispersing Müeller Hinton broth into each well. 
Subsequently, serially diluted VAN was dispensed on the 
X-axis of the 96-well microdilution plates and the test 
drugs (UA, UA-lipo, β-lap or β-lap-lipo) on the Y-axis, to 
obtain a final concentration equal to the MIC or dilutions 
lower than the MIC of the respective drugs. Finally, each 
plate received the adjusted bacterial suspension (105 CFU/
mL) and the plates were then incubated at 35 °C for 24 h. 
The data were interpreted after calculating the 
Fractional Inhibitory Concentration Index (FICI) as 
follows: 
SFICI = FICA + FICB = MICAB/MICA + MICBA/MICB
where MICAB equals the MIC of drug A in combination 
with drug B, MICA is the MIC of drug A alone, MICBA 
equals the MIC of drug B in combination with drug A 
and MICB is the MIC of drug B alone. The interaction 
is considered synergic for FICI ≤0.5; additive for 
0.5<FICI≤1, indifferent for 1<FICI≤2 and antagonistic for 
FICI>2 (An et al., 2011). The checkerboard assays were 
also carried out in triplicate. 
Etest
The in vitro interactions between VAN and UA, 
UA-lipo, β-lap or β-lap-lipo were also evaluated by an 
epsilometer test (Etest) (Sopirala et al., 2010). The Etest 
was performed with subinhibitory concentrations of active 
substances B (UA, UA-lipo, β-lap and β-lap-lipo) of ¼ 
to ½ of the respective MIC. The same clinical isolates 
used in the checkerboard test were adjusted at an optical 
density of 0.5 McFarland units. They were then seeded 
onto plates and the VAN Etest strips applied to inoculate 
Müeller-Hinton agar plates containing UA, UA-lipo, β-lap 
or β-lap-lipo, as well as plates without active substances 
(control). The plates were then incubated at 35 °C for 24 h. 
The results were interpreted as follows: indifferent effect 
if the MIC of VAN changed within a 1-fold dilution in 
the respective plate; an additive effect for a reduction of 
2-fold dilutions; and synergic effect for 3-fold dilutions 
according to the manufacturer’s recommendations (Etest 
application sheet EAS 021). All the experiments were 
performed in triplicate. 
Statistical analysis 
To compare the data of the in vitro interaction assay, 
one-way analysis of variance (ANOVA) was applied using 
the Tukey multiple comparison procedure. The statistical 
data were considered significant at p < 0.05.
RESULTS
Characterization of liposomes 
β-lap-lipo and UA-lipo had a pH of 7.6 and 7.5, 
particle size of 110.4 ± 0.7 nm and 121.3 ± 1.8 nm, PDI 
of 0.319 and 0.362, zeta potential of + 22.4 ± 1.8 mV and 
+11.8 ± 0.5 mV, and %EE of 97.4 ± 1.1% and 99.0 ± 2.7%, 
respectively.
In vitro antimicrobial activity
The MIC and MBC values of VAN, UA and UA-lipo 
against MRSA clinical isolates are shown in Table I. As 
expected, the MIC values of VAN were between 0.25 and 
2 µg/mL. The MIC values of UA and UA-lipo ranged from 
8 to 32 µg/mL and 4 to 8 µg/mL, respectively. 
In vitro interaction assays
Checkerboard method
FICI values obtained in the interaction assays 
of VAN with UA, UA-lipo, β-lap or β-lap-lipo against 
MRSA clinical isolates are depicted in Figure 1. With 
regard to the interaction of VAN with UA, an additive 
interaction for almost all the MRSA clinical isolates was 
evident (FICI = 0.51), except for LMB 03, which exhibited 
synergic interactions (FICI = 0.26). The UA-lipo/VAN 
association had a synergic effect on all the MRSA clinical 
isolates tested (FICI = 0.25-0.30). Statistically significant 
differences between the interactions of UA/VAN and UA-
lipo/VAN were found. 
With regard to the in vitro interaction between VAN 
and β-lap, synergism was found and the profile remained 
unaltered when β-lap was encapsulated into liposomes 
(FICI = 0.26-0.50), whereas the predominant FICI for 
other combinations involving these two compounds was 
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0.5 (Figure 1). The statistical analysis showed significant 
differences between the interactions of β-lap/VAN and 
β-lap-lipo/VAN. 
Moreover, there were no statistically significant 
differences between the interactions of β-lap-lipo/VAN 
and UA-lipo/VAN, suggesting that the encapsulation of 
drugs into liposomes associated with VAN represents a 
promising therapy against MRSA. 
Etest
The results of the interactions of VAN with UA, 
UA-lipo, β-lap or β-lap-lipo against MRSA clinical 
isolates using the Etest are listed in Table II. The data 
obtained using the Etest confirmed the results found with 
the checkerboard method in 82.5% of the analysis. Only 
seven of the forty combinations were not consistent with 
the other method (17.5%). The discordant combinations 
were VAN/ ½ MIC UA-lipo for LMB 08; VAN/ ¼ MIC 
UA-lipo for LMB 01 and LMB 08; VAN/ ½ and ¼ MIC 
β-lap for LMB 08, as well as VAN/ ¼ MIC β-lap-lipo for 
LMB 01 and LMB 06. 
DISCUSSION
The liposomal formulations exhibited suitable 
physicochemical characteristics, such as particle size, 
PDI, zeta potential and pH, for future in vivo therapeutic 
applications (Pinto-Alphandary, Andremont, Couvreur, 
2000). Since the administration route of these nanocarriers 
is intravenous, formulations must have a pH within the 
range of neutrality, particle size of below 200 nm and 
PDI below 1 to prevent harmful effects on patients, such 
as acid-base disorders or vessel obstruction (Hinrichs 
et al., 2006; Elsabahy, Wooley, 2012). In addition, the 
positive surface charge of the liposomes is important for 
their electrostatic attraction with the negative cell wall 
of bacteria (Xia, Kohler, Peschel, 2010). Finally, the 
high encapsulation rate of AU and β-lap in liposomes 
demonstrated the efficiency of the encapsulation method 
used in this study. 
Regarding the susceptibility of MRSA clinical 
isolates to VAN, the CLSI (2014) defines susceptible 
strains as having MICs ≤ 2 µg/mL, intermediate as MICs 
4-8 µg/mL and resistant as MICs ≥ 16 µg/mL. The MRSA 
clinical isolates tested in the present study showed in vitro 
VAN susceptibility (MICs ≤ 2 µg/mL). A low efficacy of 
VAN against MRSA clinical isolates at relatively high in 
vitro MICVAN values (1-2 µg/mL) is correlated with VAN 
treatment failures and mortality of patients with MRSA 
infections. In these cases, novel approaches, as well as 
combination therapy, are suitable for the treatment of 
MRSA (Moise et al., 2007; Lodise et al., 2008; Casapao 
et al., 2015).
The MIC values of UA against MRSA were 
consistent with data on UA antimicrobial activity 
previously reported in the literature. In 1995, Lauterwein 
et al. found usnic acid MICs in the 8 to 16 µg/mL range 
against MRSA clinical isolates. 
UA-lipo had heightened bacteriostatic activity 
when compared with pure UA, showing a decrease in 
MIC from 8-32 µg/mL to 4-8 µg/mL. One explanation 
for the improvement in antimicrobial activity produced 
by the encapsulation of UA into liposomes is the possible 
fusion of the nanostructured systems with the cell wall 
of S. aureus, which allows an increased amount of 
active substance within the bacterial cells. In fact, UA 
is able to cross biological membranes by modulating its 
solubility through protonation/deprotonation of 3-OH in 
a physiological pH environment (Sharma, Jannke, 1996). 
As recently reported for in silico simulation studies, UA, in 
its usnate ionic form, causes perturbation in phospholipid 
bilayers, which undergo a lamellar to nonlamellar 
transition phase (Nadvorny, Da Silva, Lins, 2014).
In the interaction study by the checkerboard method, 
the encapsulation of UA into liposomes appeared to be a 
promoter factor for synergism. The combination therapy 
of VAN with other antibiotics has clearly emerged as a 
potential approach to overcome the decrease in bacterial 
TABLE I - Antibacterial activity of vancomycin, usnic acid and 
liposomes containing usnic acid against methicillin-resistant 
Staphylococcus aureus clinical isolates
MRSA  
Strains
MIC/MBC (µg/mL)
VAN UA UA-lipo
LMB 01 0.5/2 31/>128 8/>128
LMB 02 0.5/1 31/>128 8/>128
LMB 03 2/2 31/128 8/>128
LMB 04 0.5/1 31/128 8/>128
LMB 06 0.5/2 8/16 4/>128
LMB 07 0.5/0.5 31/32 4/32
LMB 08 0.5/0.5 31/32 8/32
LMB 11 0.5/1 31/128 8/32
LMB 12 0.25/0.5 8/32 8/>128
LMB 13 0.5/0.5 31/32 8/32
MIC: Minimum Inhibitory Concentration; MBC: Minimum 
Bactericidal Concentration; MRSA: methicillin-resistant 
Staphylococcus aureus; LMB: Laboratório de Microbiologia e 
Imunologia, CAV-UFPE, Brazil; VAN: vancomycin; UA: usnic 
acid; UA-lipo: UA-loaded liposomes. 
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susceptibility to this reference drug. Our findings thus 
suggest UA, especially encapsulated into liposomes, 
as a possible promoter to improve VAN antimicrobial 
activity and proved more significant than results obtained 
by Segatore et al. (2012). The cited authors analyzed the 
interaction of UA with five antibiotics used in clinical 
therapy (clindamycin, erythromycin, gentamicin, oxacillin 
and levofloxacin) against four MRSA clinical isolates. 
TABLE II - In vitro interactions between VAN and UA, UA-lipo, β-lap or β-lap-lipo using Etest
MRSA strains
MICVAN (µg/mL)
VAN VAN/UA VAN/UA-lipo VAN/β-lap VAN/β-lap-lipo
½ × MIC 
UA
Int
¼ × MIC 
UA
Int
½ × MIC 
UA-lipo 
Int
¼ × MIC 
UA-lipo 
Int
½ × MIC 
β-lap 
Int 
¼ × MIC 
β-lap 
Int
½ × MIC 
β-lap-lipo
Int
¼ × MIC 
β-lap-lipo 
Int
LMB 01 0.5 0.12 A 0.12 A 0.06 S 0.12 A 0.06 S 0.06 S 0.06 S 0.12 A
LMB 02 0.5 0.12 A 0.12 A 0.06 S 0.06 S 0.06 S 0.06 S 0.06 S 0.06 S
LMB 03 1 0.12 S 0.12 S 0.12 S 0.12 S 0.12 S 0.12 S 0.12 S 0.12 S
LMB 06 1 0.25 A 0.25 A 0.12 S 0.12 S 0.12 S 0.12 S 0.12 S 0.25 A
LMB 08 1 0.25 A 0.25 A 0.25 A 0.25 A 0.25 A 0.25 A 0.12 S 0.12 S
Etest: epsilometer test; MIC: Minimum inhibitory concentration; LMB: Laboratório de Microbiologia e Imunologia (CAV-UFPE, Brazil); Int: in vitro interaction; 
VAN: vancomycin; UA: Usnic acid; UA-lipo: UA-loaded liposomes; β-lap: β-lapachone; β-lap-lipo: β-lap-loaded liposomes. A: additive; S: synergistic. 
FIGURE 1 - In vitro interactions between VAN and UA, UA-lipo, β-lap or β-lap-lipo against MRSA clinical isolates using 
checkerboard method. FICI: Fractional Inhibitory Concentration Index; LMB: Laboratório de Microbiologia e Imunologia; VAN: 
vancomycin; UA: usnic acid; β-lap: β-lapachone; UA-lipo: UA-loaded liposomes; β-lap-lipo: β-lap-loaded liposomes; A: additive 
interaction; S: synergistic interaction.
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For all isolates studied, the interaction of UA with 
erythromycin, oxacillin and levofloxacin was indifferent; 
for clindamycin, the interaction with UA was synergic 
for only one isolate, yet indifferent for the other three. 
Synergic interactions of UA with gentamicin were found 
for two of the four strains and indifferent interaction for 
the other two.
The results for β-lap interactions with VAN are 
in agreement with those of Macedo et al. (2013) for 
interactions between β-lap and ampicillin, amoxicillin/
clavulanic acid, cefoxitin, ciprofloxacin or meropenem 
against five MRSA isolates. A synergism in almost all 
interactions between β-lap and antibiotics tested (FICIs = 
0.346, 0.166, 0.375, 0.384 and 0.224, respectively) was 
observed, except for the additive interaction between β-lap 
and ciprofloxacin against one isolate (FICI = 0.56).
In the past few decades, in vitro synergistic 
interactions of VAN with antimicrobial agents for 
antibacterial therapy have been reported. You et al. 
(2000) investigated the existence of synergism between 
arbekacin and VAN and compared it with the in vitro 
interaction of the classical combination of gentamicin and 
VAN against MRSA isolates resistant to gentamicin. The 
arbekacin/VAN combination exhibited a synergic effect 
against twelve of the thirteen isolates tested, whereas the 
gentamicin/VAN combination was synergistic for only 
seven. 
Some of the combinations assessed in our study 
(UA-lipo/VAN, β-lap/VAN and β-lap-lipo/VAN) seem 
to be more synergistic than the standard combination 
(gentamicin/VAN), as the combinations were synergistic 
in 100% of the MRSA isolates tested. In 2010, Mahboubi 
and Bidgoli also evaluated the in vitro interaction of 
vancomycin with natural products, such as Zataria 
multiflora essential oil, against MRSA clinical isolates. 
Similar to our results, the interaction was synergistic 
between these substances (FICI = 0.32). 
The level of agreement between the data from 
the Etest and the checkerboard methods was notable 
(82.5%) and comparable with previous studies (White 
et al., 1996; Sopirala et al., 2010). White et al. (1996) 
investigated the interaction between antibiotics against 
gram positive and gram negative bacteria using the 
Etest and checkerboard methods and observed a greater 
discrepancy of approximately 25%. Sopirala et al. (2010) 
analyzed the interaction between antibiotics against Pan-
Drug-Resistant Acinetobacter baumannii and found a 
discrepancy of around 15% between the results obtained 
from the two tests in question.
Thus, the results observed in the checkerboard 
method corroborate the Etest observation performed in our 
study and these microbial experiments suggested that VAN 
combined with UA-lipo, β-lap or β-lap-lipo synergistically 
enhanced its antibacterial activity against methicillin-
resistant Staphylococcus aureus clinical isolates.
CONCLUSION
Vancomycin exhibited synergism with UA and β-lap 
encapsulated into liposomal formulations. Therefore, 
these natural compounds encapsulated into the drug 
delivery system may be a potential therapeutic approach 
for improving the antimicrobial activity of vancomycin in 
the treatment of MRSA. Further studies in animal models 
are needed to evaluate the in vivo antimicrobial effect of 
these combinations and their potential use in the treatment 
of infections caused by MRSA.
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